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Abstract
Candida albicans is an opportunistic dimorphic yeast. This organism is pathogen associ-
ated to superficial and systemic infections. Actually, Candida albicans represents an emer-
gent pathogen especially in a patient with some immunity compromises. Added to this, 
the use of antifungal in an indiscriminate form has increased the resistance of the exist-
ing drugs. In this aspect, the nanotechnology generates the possibility of creating new 
therapeutic agents. Nanoparticles are structures of 1–100 nm with special physicochemi-
cal characteristics that allow it to function as therapeutic agents or as carriers of these. 
Palladium, silver, and gold metallic nanoparticles and iron, titanium, zinc, and copper 
oxides have been used as growth inhibitors. These nanoparticles have been proved alone 
or in form of nanocomposites. The objective of this chapter is to describe the state of the 
art of the use of nanoparticles as inhibitors of the growth of Candida albicans, as well as the 
most relevant results regarding the mechanisms involved in this inhibition.
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1. Introduction
Candidiasis is one of the most common infections worldwide. These diseases are generated 
by Candida albicans and Candida non-albicans group. Candida albicans is an opportunistic dimor-
phic yeast. It is a commensal organism in gastrointestinal, respiratory, and genitourinary 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
tracts. Normally, it is a harmless organism that can turn into an opportunistic organism in 
immunocompromised or immunologically deficient individuals [1–3].
Candida albicans represents the predominant yeast in oral, genital, and cutaneous infections 
(≥90%) [2, 4, 5]. However, the invasion of blood torrent by Candida species is the infection more 
frequently diagnosed. The frequency of Candida albicans isolated in candidemia is of 46.3%, 
followed by C. glabrata (24.4%) [3, 6]. The mortality frequency in patients with invasive candi-
demia ranges from 40 to >70%, generating a loss of about 1.7 billion dollars every year [1, 7].
For the treatment of invasive infection by Candida, few options are available. The polyenes 
(amphotericin B and nystatin) are the chosen treatment by excellence. However other antifun-
gals are used as azoles [8]. The azoles (fluconazole and itraconazole) and new azoles (ravuco-
nazole, posaconazole, and voriconazole) are selected for prophylaxis, empirical therapy, and 
diagnostic-driven therapy [9]. The use of echinocandins (caspofungin, anidulafungin, and 
micafungin) is driven to therapy on invasive candidiasis [1].
However, the adverse effects of antifungal therapy as nephrotoxicity, red blood cell (RBC) 
toxicity, and arrhythmias for amphotericin B, hepatotoxicity associated with fluconazole, 
cardiotoxicity and gastrointestinal (GIT) disturbances attributed to itraconazole, voriconazole 
exhibiting neurological and hepatic toxicities, and posaconazole shown to elevate serum ami-
notransferase levels and cause mild-to-moderate hepatic toxicity limit its use. These adverse 
effects are attributed to the action mechanism. Azoles and polyenes have ergosterol as a tar-
get from the cell membrane, and the ergosterol has a high similarity between ergosterol and 
human cholesterol [8]. Azoles inhibit the ergosterol biosynthesis, specifically the lanosterol 
14α-demethylase. This generates sterol precursor accumulation, resulting in a cell membrane 
instability and the loss of viability [3].
The echinocandins are more specific for fungi. This therapeutic antifungal inhibits the enzyme 
1,3-b-D-glucan synthase and generates the depletion of polymer synthesis and osmotic stabil-
ity loss [1, 10].
Due to the discriminated antifungal agent use, Candida albicans has developed different resis-
tance mechanisms. Three principal mechanisms have been reported: the efflux pump, which 
is a membrane transport protein that ejects the azoles out of the cell; the structural changes of 
the enzyme target, mutations on lanosterol 14 α-demethylase, changing the three-dimensional 
structure, and, as consequence, the decreased affinity for this enzyme; and the last mechanism 
is the increase in the production of the target enzyme; this generates the inhibition of only a 
portion of the enzyme, and the rest are still active [1–3, 8, 11].
On the other hand, the survival characteristics of Candida albicans in the host make this organ-
ism difficult to kill. The virulence factors include the biofilm formation capacity, the yeast-
hyphae morphogenesis, the adhesion to surfaces, and the capacity to secrete enzymes as 
hydrolases.
Because of this, the research for more specific antifungal therapies has been the focus of 
attention. In this area, the nanotechnology offers an opportunity to design and create a new 
Candida Albicans146
pharmaceutical agent that can be specific. As pharmaceutical agent nanoparticles such as cop-
per, silver, and palladium, among others, have been employed in order to inhibit the growth 
of any microorganism, in particular, Candida albicans.
The objective of this chapter is to describe the state of the art of the use of nanoparticles as 
inhibitors of the growth of Candida albicans, as well as the most relevant results regarding the 
mechanisms involved in this inhibition.
2. Candida albicans taxonomy
Fungi form one of the largest eukaryotic kingdoms; they have a very broad function of decom-
posing biopolymers and different compounds in dead or alive hosts, as well as synthesizing 
bioactive compounds. The yeast Candida albicans originally was described as Blastomycetes 
class belonging to Monilial order and Cryptococcaceae family. Actually, with gene sequenc-
ing, the new taxonomy classifies Candida albicans into Ascomycota, (dikaryon-producing fungi), 
Hemiascomycetes subclass, and Saccharomycotina order [12, 13].
Candida albicans is a common commensal on mucosal surfaces under normal conditions, 
mainly of the gastrointestinal and vaginal tracts. The commensal stage is frequently described 
as harmless to the host, and the fungus is controlled by the normal microbiota, epithelial bar-
riers, and the innate immune system [14, 15]. This is the most important opportunistic medi-
cal pathogenic fungus, causing candidiasis, which is an acute, subacute, or chronic infection 
involving any part of the body [15]. The weakening of the defense mechanisms of the host and 
the adaptation capacity of the microorganism turn this fungus into an aggressive pathogen, 
starting with superficial infections into a systemic process, mainly in immunosuppressed or 
HIV patients [16].
3. Candida albicans cell wall
Candida albicans cell wall is composed mainly of carbohydrates; three basic main constituents 
are polysaccharides:
1. Branched polymers of glucose with β-1,3 and β-1,6 bonds, they are called β-glucans.
2. Unbranched polymers of N-acetyl-D-glucosamine (GlcNAc) with β-1,4 bonds; the chitin, 
which contributes to the fiber insolubility; and theβ-1,3 glucan-chitin complex, which is 
the major constituent of the inner wall. β-1,6 glucan links the components of the inner and 
outer walls; thus, chitin and β-1,3 are structural polysaccharides and convey strength and 
shape to the cell wall [15, 17, 18].
3. Finally mannose polymers, mannans, covalently associated with proteins (glucomannan 
proteins).
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The mannan of the outer cell wall is less structured but allows this fungus breakage of epi-
thelial barriers or dysfunction of the immune system converting Candida albicans from a com-
mensal to a pathogen. The cell walls also contain proteins, 6–25%, and minor amounts of 
lipids, 1–7% [15, 17, 18].
This arrangement is responsible for its cell morphology and provides protection to the cell 
against physical, chemical, and biological (immune host system) aggression [16].
Likewise, the cell wall participates in both growth and morphological transitions between 
yeast and hyphae; this conversion from the unicellular yeast to multicellular filamentous 
fungus is essential for Candida virulence [19]. It has cell surface proteins linked to glyco-
sylphosphatidylinositol (GPI) [20], including an N-terminal signal sequence and a C-terminal 
GPI-anchor addition signal; some of these proteins are secreted to the extracellular environ-
ment, but do not remain cell associated. Some of them are hydrolytic enzymes, which hydro-
lyze complex substrates into small units, to carry out into the cell as a source of nutrition. 
If these polymers are host targets, all of these facilitate colonization or invasion of Candida 
albicans, and then such enzymes also function as virulence factors [17]. For therapeutic strate-
gies, to establish the functional relationships between Candida albicans cell wall’s proteins and 
virulence is a challenge [20].
4. Candida albicans virulence factors
Candida spp. invade several anatomical hosts, mainly in patients who are immunocompro-
mised or debilitated. This organism expresses several virulence factors that allow the host-
pathogen interaction and that lead to the establishment of infection [21, 22].
Virulence factors include host recognition biomolecules (adhesins) due to cell surface hydro-
phobicity which enhanced adherence and resistance to phagocytosis; another important factor 
is its ability to grow either in yeast or in hyphal form (dimorphism, especially in the presence 
of N-acetyl-D-glucosamine) [23], secreting aspartyl proteases and phospholipases [21].
The phenomenon of the quorum sensing (QS) has been described as a contributor to mor-
phogenesis, playing a role in regulating the yeast to filamentous fungus; one of the condi-
tions is the dependence on cell density associated with the regulation by QS. The QS has an 
important role in the ability of Candida albicans to be virulent and survive within the host [23]. 
Candida albicans uses multiple redundant and/or synergistic signaling pathways to integrate 
host signals to promote hyphal development, tissue invasion, and virulence during infection, 
exacerbating the pathogenesis of invasive candidiasis [24].
5. Candida albicans biofilm formation
Candida virulence is a result of its capacity to form biofilms on the surface of biomaterials and 
on catheters and prosthetic devices [25–27]. Candida albicans biofilms are composed of hyphae, 
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pseudohyphae, yeast cells, and an extracellular matrix, where the hyphae play an integral role 
within this complex [26]. Biofilm formation presents an initial adherence of yeast cells (0–2 h), 
followed by germination and microcolony formation (2–4 h), filamentation (4–6 h), monolayer 
development (6–8 h), proliferation (8–24 h), and maturation (24–48 h). Serum and saliva pre-
conditioning films and Candida albicans preconditioning films increased the initial attachment 
of the fungus but had minimal effect on subsequent biofilm formation [25, 28]. This kind of 
biofilm has clinical repercussions because it is the target of both chemical and immunological 
antifungals. Due of their intrinsic resistance to almost all antifungals in clinical use, increased 
resistance to this therapy, and the ability of cells within biofilms to withstand host immune 
defenses, the antifungal resistance of biofilms results most probably from the conjunction of 
several mechanisms that act in a time-dependent manner [26].
6. Candida albicans resistance mechanisms
In order for Candida albicans to survive, these microorganisms have developed diverse mecha-
nisms. Biofilm formation, enzyme modification, and the pump efflux are the mechanisms 
reported to antibiotic resistance [29]. As described previously, biofilms are a complex of cells, 
DNA, and polymeric matrix, among others. The polymeric matrix has a crucial role in the 
antifungal resistance since it does not allow antibiotic penetration inside the biofilm. This 
phenomenon helps the internal cell to survive [25].
Resistance to azole antifungal has been described in three forms: [1] change in the affinity of 
cytochrome P450 sterol 14α-demethylase (gen Erg11p), [2] increase in the enzyme expression, 
and [3] changes in the sterol desaturase. Other alterations in an enzyme involved in the cell 
wall construction have been described [29, 30].
The pump efflux ejects the azoles outside the cell, without any effect inside of it. This efflux 
is mediated by an ATP-binding cassette (ABC) and the major facilitator superfamily. This is 
a complex family of genes that involve several CDR genes, including core membrane pore 
composed by ABC segments in the membrane; two segments are in the cytosolic side, which 
provide energy to pump the antibiotic outside of the cell [25, 29, 30].
It is an important highlight that this resistance could be a derivative in the resistance to other 
antifungals.
Candida albicans resistance could be due to one or a combination of all the resistance mecha-
nisms described.
7. Nanotechnology as an antifungal
Nanotechnology is a new technology which manipulates the matter in a nanoscale order 
(1 × 10−9 m). In this order, the nanoparticles have been used as antimicrobial, as antifungal, or 
as carried molecules. Nanoparticles have a size from 1–100 nm on any of this dimension. In 
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this scale, nanoparticles have particularity physicochemical characteristics [31]. Within these 
characteristics, their electron configuration confers an extraordinary quantum effect. These 
quantum effects enhance their pharmacokinetic effect and generate nanoparticles that can be 
used as a protein, antibodies, or inclusive specific molecule carriers [32].
As an antifungal, nanoparticles show cell wall damage, an oxidative stress increase, and DNA 
interaction [33]. Nevertheless, the NPs toxicity mechanisms are dependent on the nanopar-
ticle nature, size, and shape and capping nature, among other characteristics.
This chapter reviewed some NPs characteristics such as nanoparticle nature, synthesis, size, 
and shape and their influence on the toxic mechanisms in Candida albicans and their influence 
on the virulence factors.
7.1. Silver nanoparticles
Silver has been used for several decades as a disinfectant. Inclusively, silver nitrate was used 
in burns in order to control infections. However, with the discovery of penicillin, the use of 
silver was slow. Nowadays, the increase of resistance to antifungal puts attention again on 
the use of silver as an antibiotic, though the use of silver ions implies complications in their 
solubility and availability [34].
In this sense, the silver nanoparticles (AgNPs) offer a possibility. AgNPs offer the possibil-
ity of using minimal doses and act in microorganisms which present antibiotic resistance or 
decrease the virulence factors.
The use of different AgNPs synthesis methods caused different effects. The general method 
is the salt reduction by a reducing agent. However, the addition stabilizing agent has been 
proved. The stabilizing or capping agent limits the NPs’ growth, avoids the agglomeration, 
and controls the shape, size, and superficial charge [35].
The NP synthesis by plant extract or secondary metabolites from microorganisms offers a 
new possibility. The phenolic compounds, proteins, anthocyanin, and carboxylic acid, among 
others, work as reducing agent and stabilizing or capping agent [35, 36].
The green AgNPs synthesis through the use of microorganisms as the use of Actinobacteria 
Pilimelia columellifera subsp. pallida [37], Bacillus species [38, 39], filamentous fungi Monascus 
purpureus [7], and Macromycetes as Pleurotus sajor-caju [40], as well as extract plant as Tulsi 
leaf extract [41] or extract from Phoenix dactylifera [34] has been proven. All these methods 
present inhibition of Candida albicans, with different efficiencies (Table 1).
The microorganisms Bacillus amyloliquefaciens 1853 and Bacillus subtilis 10,833 have been used 
for the AgNPs synthesis. Culture media were employed as a reducing agent. The scanning 
electronic microscopy has shown AgNPs produced with capping. Bacillus strains have been 
used in the AgNPS production. Bacillus amyloliquefaciens strain 1853 produced AgNPs with a 
size of 1.071 and other of 73.83 nm. The Bacillus subtilis strain 10,833 produced tree population 
sizes of AgNPs at 1.863, 10.866, and 135.78 nm. AgNPs produced by both microorganisms 
were employed to evaluate the Candida albicans inhibition. No differences were found between 
AgNPs; inclusive addition of antibiotic with the AgNPs does not improve the inhibition [38].
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Inhibition test NPs size 
(nm)
Synthesis method Capped Reference
18 mm (inhibition zone) 15–20 Cassia roxburghii + Ketoconazole NR Moteriya et al. 
2017 [42]
64 μg/mL (MIC) 12.7 Pilimelia columellifera subsp. 
pallida SL19
Proteins Wypij et al. 2017 
[37]
16.7 ± 0.25 mm (inhibition 
zone)
2–8 Monascus purpureus NR El-Baz et al., 
2016 [7]
10 μg/mL (BIC) 40–55 Dodonaea viscosa and Hyptis 
suaveolens
Detection of 
functional groups 
as phenol, 
alcohol, proteins, 
heterocyclic 
amines
Muthamil et al. 
2018 [43]
40 μg/mL (MIC) 5–95 Bacillus safensis Proteins Lateef et al. 2015 
[38]
12 mm (inhibition zone 
with 30 μL of solution)
18–46 Gracilaria corticata Detection of 
functional groups 
as alcohol, 
carbonyl, amino 
groups
Kumar et al. 
2013 [44]
250 μg/mL (MIC) and 
500 μg/mL (MFC)
3.77–33.22 Pleurotus sajor-caju NR Musa et al. 2018 
[40]
60 μg/mL (MIC
90
) and 120 
(MFC)
2–7 Tulsi leaf extract NR Khatoon et al., 
2015 [45]
20 mm (inhibition zone 
with 80 μg/20 mL)
21.65–41.05 Phoenix dactylifera Proteins Oves et al. 2018 
[34]
75 ppm reduce 
83%/150 ppm (MFC)
70 Red cabbage Anthocyanin 
compounds
Ocsoy et al. 2017 
[46]
08 μg/mL (MIC) 9–130 Enterococcus faecalis NR Ashajyothi 2016 
[47]
40–60 μg/mL(MIC) 4–39 Citrus lemon aqueous Juice + 
CTAB
Surrounded by 
a layer
Rahisuddin et al. 
2015 [48]
10.8 ± 0.8 (inhibition zone) 12–85 Clove extract Detection of 
functional groups 
such as methoxy, 
alcohol, carboxilic 
acid, aliphatic 
group
Parlinska-
Wojtan et al. 
2017 [49]
21–12 cm in combination 
with antifungal (inhibition 
zone)
10–90 Flower broth of Tagetes erecta NR Padalia et al. 
2015 [50]
12.14 μg/mL (MIC) 47.0 ± 2.0 J. curcas Protein layer Kumar et al. 
2017 [51]
10.78 μg/mL (MIC) 7.6 ± 0.5 L. grandis
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Clove extract was used in order to produce AgNPs. The high content of eugenol, β- caryophyllene, 
humulene, chavicol, methyl salicylate, α-ylangene, and eugenone;  flavonoids such as eugenin, 
rhamnetin, kaempferol, and eugenitin; triterpenoids like oleanolic acid, stigmasterol, and 
campesterol; and several sesquiterpenes allowed the clove to act as a reducing and capping agent 
in AgNPs synthesis. The DLS analysis showed AgNPs size of 12 and 85 nm. The AgNPs pro-
duced to generate a complete inhibition of Candida albicans in 40-fold dilution were applied. The 
results obtained suggest that the functional groups’ incorporation into the AgNPs generates a 
synergism between clove and NPs [49].
In order to evaluate the AgNPs effect on biofilms, some AgNPs have been evaluated. As 
described, biofilms are a Candida albicans virulence factor. The change from yeast to hyphae 
is crucial for the biofilm process. In this process, Candida albicans produces a polysaccharide 
matrix, carbohydrates, proteins, and signaling molecules [43]. Changes in the structural bio-
film conformation of Candida albicans exposed to AgNPs were reported [28, 51, 53, 54].
The use of latex plants in the AgNPs green synthesis was proved. J. curcas and L. grandis 
extracts produced AgNPs with a size of 47 ± 2.0 nm and 7.6 ± 0.5 nm, respectively. The Fourier 
transform infrared (FTIR) spectra suggest the incorporation of phenolic OH, amides, amines, 
and aldehyde in the AgNPs as a stabilizing agent. The smallest AgNPs showed a better effect 
in plankton and biofilms of Candida albicans than the big ones. The AgNPs synthesized proved 
to be efficient in the inhibition of biofilm formation, changes in morphology and cell lysis 
when candida albicans was exposed [51].
Also, silver nitrate chemical reduction by sodium citrate was evaluated in intermediate and 
mature Candida albicans biofilms. The preformatted biofilms were exposed to 54 μg/mL of 
AgNPs. After 5 h of exposition, biofilms showed a decrease in the number of viable cells, and 
no differences were found in intermediate or mature biofilm [28].
Inhibition test NPs size 
(nm)
Synthesis method Capped Reference
70% fold increase 
(combination with 
antifungal, inhibition zone)
1.836–135.78 B. subtilis 10,833 NR Ghiut et al. 2018 
[39]
50% fold increase 
(combination with 
antifungal, inhibition zone)
1.012–73.83 B. amyloliquefaciens NR
14 mm(inhibition zone) 5–10 Ocimum sanctum + CTAB Not visible Aazam and 
Zaheer 2016 [35]
30 μg/mL (MIC) 4–36 Actinobacterial strain SF23 NR Anasane et al. 
2016 [52]
40 μg/mL (MIC) 8–60 Actinobacteria C9 NR
MIC, minimal inhibition concentration.
MFC, minimal fungicide concentration.
NR, not reported.
BIC, biofilm inhibitory concentration.
Table 1. Biogenic synthesized AgNPs against Candida albicans.
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The results obtained show the importance of the NPs size, being the smallest nanoparticles 
which show the highest inhibition [51]. Lara et al. (2015) showed that biofilm exposed to 
AgNPs exhibits a few Candida albicans filamentous formations. Electron microscopy analysis 
showed AgNPs accumulation and internalization [55].
Besides the AgNPs effect in biofilm, the AgNPs have been used alone showing the inhibition, 
cell wall damage, and incorporation of Ag into the cell. It was used in combination with dif-
ferent antifungals amphotericin b [51, 56] or nystatin and chlorhexidine digluconate, show-
ing a synergic effect [54]. Other molecules as cationic carboxilane have been used, proving a 
high Candida albicans inhibition with small AgNPs concentration [1.8 mg/mL; [57]]. Also, the 
AgNPs have been capped with L-3,4-dihydroxyphenyl-alanine, showing a minimal fungicide 
concentration of 31.2–62.5 μg/mL [58].
The direction in the investigation with silver nanoparticles has been driven in the green syn-
thesis due to the low toxicity generated in the human cell and the increase of the toxicity in 
bacteria and yeast [59]. Their chemical characteristics as a metallic oxidative state and super-
ficial area, among others, allow the NPs to interact with the microorganism and inhibit their 
growth.
7.2. Zinc oxide nanoparticles
Due to ZnO low toxicity, ZnO has been used in a medical device such as drug carriers, anti-
bacterial agents, and bioimaging probes, among others. For this reason, the ZnO nanoparticles 
(ZnONPs) have been used in Candida albicans control. The ZnONPs application is reflected by 
the annual production between 550 and 5500. This is more than 10–100 times higher than 
any other nanoparticle [60]. As the AgNPs, the ZnONPs characteristics depend on the size, 
synthesis method, and superficial charge, among others [61]. In order to control these char-
acteristics, the green synthesis method has been used to fabricate ZnONPs with a size, shape, 
and superficial charge with the desirable characteristic [62, 63].
A promissory ZnONPs application area is their use as antimicrobial. Their effect has been 
evaluated in soil, plants, bacteria, and fungi [60, 64–66]  ZnONPs different synthesis methods 
in ZnONPs have a big influence in the Candida albicans inhibition [68].
The use of Atalantia monophylla extracts produced ZnONPs 30 nm that have effect inhibition 
in Candida albicans growth. The author proposed the ZnONPs interaction with the cell wall, 
penetration to the cell, ion liberation, and the oxidative stress production, triggering the pro-
tein, lipid, and DNA oxidation [67].
The microwave aqueous extract from Suaeda aegyptiaca produced ZnONPs with a size of 
80 nm with a capping produced by metabolites from the plant. The effect of the capping was 
studied. ZnONPs produced by precipitation method were studied and compared with the 
plant extract produced. ZnONPs Suaeda aegyptiaca produced a major inhibitory effect than the 
ZnONPs without capping agent, suggesting a synergic effect [68].
Extracts for different plants have been proved to synthesize ZnONPs in order to evaluate the 
toxicity of the resulting nanoparticles in Candida albicans inhibition (Table 2).
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ZnONPs hybrid has been synthesized using chitosan, gelatin, and polystyrene, among others 
[75–77].
Dhillon et al. 2014 [75] used chitosan as a capping and bridge to carry on citric acid, glycerol, 
starch, and whey powder using the nanospray drying method. The ZnONPs produced have a 
size range of 93.2–402.5 nm. The smallest ZnONPs were the chitosan starch NPs. Aggregation 
effect was observed in the largest ZnONPs; this phenomenon could be explained by the 
superficial charge. However, these ZnONPs have a small effect in Candida albicans inhibition.
Collagen was used as a reducing and capping agent. The ZnONPs produced with this 
method showed a size between 20 and 50 nm negatively charged. ZnONPs coated by collagen 
Inhibition test NPs size 
(nm)
Synthesis method Capped Reference
24 mm (inhibition zone) 30 Atalantia 
monophylla
NR Vijayakumar et al. 
2018 [67]
80 μM (MIC)/>2590 μM (MFC) 8 Chelidonium majus NR Dobrucka et al. 2018 
[69]
34 ± 1.28 mm (inhibition zone with 
100 g/ml)
32–40 Glycosmis 
pentaphylla
Alkane, C=O 
stretching, other 
groups
Vijayakumar et al., 
2018 [70]
25 μg/mL (MIC)/50 μg/mL (MFC) 18 Azadirachta indica Proteins Elumalai and 
Velmurugan 2015 
[71]
Strong activity 36 S. myriocystum Protein, carbohydrates, 
flavonoids, tannins, 
mannitol
Nagarajan and 
Kuppusamy 2013 
[72]
12.5 mm (inhibition zone with 
150 mg/ml)
68.64 Cassia auriculata Alkene, alcohol, ether, 
and alkane
Padalia et al. 2018 
[73]
20.3 ± 0.57 mm (inhibition zone 
with 200 μg/mL)/25 μg/mL (MIC) 
50 μg/mL (MFC)
10–30 Vitex trifolia Proteins, alkanes, 
aromatic group
Elumalai et al. 2015 
[71]
18.01 mm (inhibition zone 100 μg/mL) 80 Suaeda aegyptiaca Alcohol, aldehyde, 
amine
Rajabi et al. 2018 
[68]
Inhibition test NPs size 
(nm)
Synthesis method Capped Reference
24 mm (zone inhibition) 30 nm Atalantia 
monophylla
NR Vijayakumar et al. 
2018 [67]
80 μM (MIC)/>2590 μM (MFC) 8 nm Chelidonium majus NR Dobrucka et al. 2018 
[74]
MIC, minimal inhibition concentration.
MFC, minimal fungicide concentration.
NR, not reported.
Table 2. Biogenic synthesized ZnONPs against Candida albicans.
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showed a MIC of 99.7 ± 0.99 μg/mL, whereas the control with zinc acetate showed an MIC of 
297.9 ± 2.0 μg/mL. Biofilms exposed to increase the concentration of ZnONPs showed inhibi-
tion as a result of the ZnONPs concentration [78].
Gelatin was used for the ZnONPs as well. ZnONPs produced with gelatin showed a diameter 
of 20 nm with a negative superficial charge. The ZnONPs produced were employed to biofilm 
exposition. ZnONPs in a concentration of 50 μg/mL showed a thickness diminution, resulting 
in a weak adherence biofilm compared with the biofilm treated with fluconazole [72].
Also, egg albumin was used as a ZnONPs template. The synthesis method produced spherical 
ZnONPs with a range between 10 and 20 nm. The FITR analysis showed the interaction of egg 
albumin and ZnONPs. In this work, ZnONPs characterization in the culture media showed 
importance. The use of 45 μg/ml in Sabouraud’s dextrose (SD) nutrient media does not signifi-
cantly affect ZnONPs stability, size, and integrity. The synthesized ZnONPs showed Candida 
albicans inhibition in a dose-dependent manner. Changes in the Candida albicans morphology 
show cavity formation in cells exposed to 15 μg/ml [79].
ZnONPs were evaluated both alone and as a part of nanocomposites with polystyrene. 
The use of ZnONPs alone showed Candida albicans inhibition. However, when ZnONPs 
are used in nanocomposites, a major concentration of ZnONPs to inhibit Candida albicans is 
necessary [77].
Nanocomposites with ZnONPs have been produced with different materials in order to 
increase the growth inhibition of microorganisms [45, 46]. However, the results of the anti-
fungal activity were contradictory; ZnONPs capped by surfactant in cotton fiber have proved 
the inhibition of Candida albicans in 94% [68], while the incorporation of ZnONPs in polylactic 
acid films does not inhibit the Candida albicans growth [80].
The principal ZnONPs toxicity mechanisms reported are (1) ion liberation, (2) interaction of 
ZnONPs with the cell wall, and (3) stress oxidative generation [81]. The ion liberation and the 
interaction of NPs with the cell trigger the generation of oxidative stress; with that the cell lost 
their viability [79].
7.3. Copper oxide nanoparticles
Copper exhibits good characteristics such as its antimicrobial activity, chemical stability, and 
thermal resistance. Due to their toxicity characteristic, copper has been used by Egyptians for 
water disinfection. The Aztecs used copper to treat sore throats, and the Persian and Indians 
used it to treat eye infection and venereal ulcers [82].
Copper has an advantage in comparison with other materials, is cheaper than any other, and 
is easy to oxidize to copper oxide nanoparticles (CuONPs). The CuONPs can easily make 
nanocomposites with polymers, macromolecules inclusive of other metals [83, 84].
The CuONPs have recovered importance in the investigation due to their low cost and the 
variety of applications. CuONPs have been used in the pharmaceutical, medicine, and elec-
tronic industries, among others.
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Diverse synthesis methods have been proved to create CuONPs including chemical [85], elec-
trochemical [86], and green synthesis [87].
The synthesis method influences the characteristics as the size, shape, and agglomeration of 
the CuONPs [88].
CuONP electrochemical production with different solvents and reaction times produces dif-
ferent NPs sizes from 3 to 200 nm. The CuONPs were obtained in water-acetonitrile, with 
sodium hydroxide as the electrolyte. The CuONPs obtained in these conditions showed a 
size around 20 nm. The Candida albicans exposition to 25 and 50 μg/ml generates a delay in 
the growth curves. Added to that, 50 μg/ml inhibited completely Candida albicans growth [86].
CuONPs prepared by precipitation method coated with acetate were evaluated together with 
fluconazole. CuONPs coated with acetate were more toxic than CuONPs without coating. 
CuONPs in combination with fluconazole showed the complete Candida albicans inhibition. 
The fractional inhibitory concentration index (FICI) suggested the additive to moderate syn-
ergism between CuONPs and fluconazole [89].
The use of dispersant as ethylene glycol and Tween 80 proved to be efficient in the production 
of CuONPs capable to the Candida albicans growth inhibition. Inhibition with CuONPs was 
more efficient than the exposition to itraconazole [90]. Also, the effect of CuONPs was evalu-
ated in Candida albicans from oral cavities [91], showing that strain isolated from the patients 
needs until 1000 ppm to generate an inhibitory effect in Candida albicans.
CuONPs capped with pyrimidine derivatives have shown a size of 10 nm. The CuONPs 
showed interaction with DNA and antioxidant activity. However, the CuONPs showed 
Candida albicans inhibition [92].
Nanocomposites with the incorporation of Fe [93] Cd and Ba CuONPs [94], as well as the 
incorporation of CuONPs into cotton fiber [95, 96], polyurethane [97], polyester [98], copoly-
mer microgel [99], and open polyurethane foams with starch powder [100], have been proved 
be efficient in the Candida albicans growth inhibition.
As in the other nanoparticles, the green synthesis has captured the investigators’ attention. Its 
methodology does not produce toxic subproduct in the nanoparticle production, and it covers 
the nanoparticles avoiding the agglomeration [31, 84, 87].
Extracts of garlic and ginger have been used for the oxidation of copper. Garlic produces the 
smallest CuONPs, with a size around 14.62–22.80 nm. However, ginger shows a big quantity 
of very small nanoparticles. Candida albicans has shown major inhibition when exposed to gin-
ger ethanol extract NPs [101]. Few reports about the use of biological extract for the synthesis 
of CuONPs that inhibited Candida albicans were founded (Table 3).
Cu2+ ions realized from CuONPs are the principal toxicity mechanisms reported. However, it 
is not the only one. Some authors reported the CuONP accumulation in the cell wall as well 
as the oxidative stress increase. However, more studies are necessary in order to understand 
the NPs toxicity mechanisms.
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7.4. Other nanoparticles
Other metal nanoparticles as gold [AuNPs, [36]], palladium [PdNPs, [91]], and selenium 
[SeNPs, [92]], among others, have been proven. The microorganisms’ elimination by all these 
NPs has been proved to be effective.
Chemical reduction of palladium salt has produced PdNPs in an average size of 9 nm (±3.9 nm). 
The PdNPs showed a significative Candida albicans growth reduction at 150 ppm [107].
SeNPs were prepared by the reduction of selenium chloride inside K. pneumoniae. This syn-
thesis produced SeNPs with a size range from 90 to 320 nm. The concentration necessary for 
growth inhibition of Candida albicans was 2000 μg/mL [109]. Another strategy for the Candida 
albicans inhibition induced the SeNPs formation inside of Lactobacillus and then used them 
as an antifungal. This strategy worked with L. plantarum and L. johnsonii. Candida albicans 
exposed to both microorganisms becomes more efficient than bacterium without NPs [108].
Schiff base ligand 2-((4,6-dihethoxypyr-imidine-2-yl)methyleneenamino)-6-methoxyphenol 
has been used in order to capped AuNPs and platinum nanoparticles (PtNPs). Nanoparticles 
synthetized presented a layer. The NPs showed a granular and spherical shape with size of 
38.14 ± 4.5 and 58.64 ± 3.0 nm, respectively. Both nanoparticles showed greater inhibition than 
amphotericin [110].
Biogenic PdNP production with watery extract of Moringa oleifera flower was evaluated for 
the Candida albicans inhibition. However, these PdNPs had no effect in Candida albicans [111].
Candida albicans exposition to tellurium NPs produces complete inhibition with of ≥2000 μg/
mL. Besides, the results showed a squalene accumulation and increase in the expression levels 
of the ERG1 gene of squalene monooxygenase enzyme [112].
Inhibition test NPs size (nm) Synthesis method Capped Reference
15.0 c ± 0.57735 (inhibition zone with 
62 μg/mL)/1.93 ± 0.76376 (MIC)
31.7 Alginate NR El-Batal et al. 
2018 [102]
10.5 (zone inhibition) 26 ± 4 Acalypha indica NR Sivaraj et al. 
2014 [103]
22.5 mm (inhibition zone) Nanostructures
~8000
Viburnum opulus Cu
3
(PO4)
2
3H
2
O
Ildiz et al. 
2017 [104]
20 mm (inhibition zone with 50 μg/mL) NR Sargassum polycystum NR Vishnu et al. 
2016 [105]
0.15 Log
10
 growth reduction 22 ± 1 nm Cellulose, chitosan, 
and keratin 
nanocomposites
Cellulose, 
chitosan, and 
keratin
Tram et al., 
2017 [106]
Table 3. Biogenic synthesized CuONPs against Candida albicans.
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7.5. Nanoparticle characteristics and toxicity and Candida albicans inhibition 
growth
The most important NPs characteristics are the size, shape, composition, superficial charge, 
and hydrodynamic. These characteristics directly influence their capacity to interact with the 
molecules or cells. Ocsoy et al. (2017) [46] indicate that the size is strictly related to charge 
density. The smallest of the NPs has the biggest charge density. This explains the big attrac-
tion between small NPs and their agglomeration. The NPs agglomeration is a phenomenon 
that changes their capacity to work as a caring or their toxicokinetic characteristic [33, 107]. 
In order to improve the distribution and decrease the agglomeration, a surfactant as Pluronic 
F® has been added to the synthesis process (Figure 1). Other surfactants as CTAB, SDS, cation 
surfactants [113], or PVP have been proved to be efficient [114].
Another synthesis methodology that improves these characteristics is the use of subproducts 
from plants, algae, bacteria, fungi, yeast, etc. [115]. The high content of proteins, reducing 
sugars or anthocyanins, works as reducing agent; additionally, some of these molecules are 
adhered in the NPs surface [31]. This addition gives different characteristics to the NPs pro-
duced by chemical reduction. The NPs obtained with biogenic methods offer homogeneous 
NPs with antioxidant characteristics that allow the addition of other molecules and control 
their toxicity characteristics.
The biogenic NPs production has proven to be efficient inhibiting the Candida albicans 
growth (Tables 1–3). The differences in the concentration necessary to inhibit their growth 
are directly related to NPs size, the capping nature, and the microorganisms evaluated [116]. 
These are evident in the work of Anasane et al. 2016 [52] et al. (2013), where two microorgan-
isms were evaluated in the production of AgNPs, obtaining two NPs sizes. The AgNPs pro-
duction by the strain SF23 was smaller than that produced by the strain C9. Candida albicans 
presented an MIC of 30 μg/mL with the small AgNPs (size 4–36 nm). Wypij et al. (2017) [37] 
reported the AgNPs synthesis with Pilimelia columellifera subsp. pallida SL19, with a capping 
Figure 1. Scanning electronic microscopy of PdNPs produced by chemical reduction. (A) Without surfactant. (B) With 
Pluronic F® (5% W/V).
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of proteins. The AgNPs size was on average 12.7 nm with a growth inhibition of 64 μg/
mL. Tulsi leaf extract has been used to produce AgNPs with a size of 2–7 nm. The fungicide 
concentration in the AgNPs produced was of 120 μg/mL [25]. The production of ZnONPs by 
Azadirachta indica [61], Vitex trifolia [64], and Suaeda aegyptiaca [65], among others (Table 2), 
has been evaluated. The extract produced different ZnONPs sizes and capping (Table 2) 
that influence the growth inhibition.
Due to the NPs size (nanometer scale), diverse toxicity mechanisms have been proposed 
(Figure 2). One is the direct interaction of the nanoparticle with the cell membrane. The inter-
action of NPs microorganism is allowed by the NPs superficial charge but also the micro-
organism superficial charge. This interaction generates disruption of the cell wall and the 
leakage of ions and the intracellular material with the microorganism’s death [117–119].
Consequent to NPs dilution, the ion interaction with the cell is another toxicity mechanism. 
The ions are incorporated into the cell, and they could interact with thiol groups of proteins 
and enzymes leading to the inhibition of crucial biological activities [82]. Also, the NPs inter-
nalization has been reported; this generates the interaction of NPs and ions with molecules 
of biological importance as DNA or enzymes [33, 120]. Inside the cell, the NPs or the ions 
provoke Fenton’s type reaction. Due to this, the oxidative stress increases, and the proteins, 
lipids, and DNA release (Figure 2).
Figure 2. NPs toxicity mechanisms induced in Candida albicans. (1) NPs adhesion in the cell membrane causing disruption 
in the membrane and death. (2) NPs introduction to the cell with their posterior degradation and ion release. (3) NPs 
ROS generation outside the cell. (4) NPs and ions ROS generation in interaction with mitochondria. (6) Membrane lipid 
peroxidation with nucleus damage. (7) DNA damage by NPS and ions ROS generation.
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Khan et al. (2014) [121] write “when CoFe
2
O
4
P NCs gained a higher energy than Eg, the 
electrons (e−) of CoFe
2
O
4
P NCs were promoted across the band gap to the conduction band 
(Ec), which creates a hole (h+) in the valence band (Ec). These e− in the E
C
 and holes in the 
Ev possibly have high reducing and oxidizing powers, respectively.” These electron move-
ments generate the NPs reactivity and the oxidative stress generation. The same phenomenon 
is reported by Setyawati et al. (2014) [122] for TiONPs. These NPs adsorbed UV light, and 
the adsorbed UV light generates electron excitation, creating a hole in the valence band. The 
electrons and holes migrate to NPs superficies where they can react with oxygen or water 
generating oxidative stress. The superficial e− generates the liberation of hydroxyl increasing 
the mitochondria membrane depolarization and liberation of cytochrome c. Added to this, the 
results show DNA damage [120]. However, the oxidative stress is not the only mechanisms 
involved in the AgNPs toxicity; also the membrane fluidity, ergosterol content, and cellular 
and ultrastructure morphology are altered [123]. The squalene monooxygenase expression in 
Candida albicans exposed to TeNPs showed an increase [112]. The squalene monooxygenase 
catalyzes the conversion of squalene to 2,3-oxidosqualene; inhibition in this step generates the 
squalene increase and the disruption of the Candida albicans cell wall [107].
8. Conclusion
The antibiotic resistance increase in many microorganisms has encouraged researchers to 
focus their efforts on the synthesis and design of multiple effective compounds in order to 
combat the resistance mechanism of microorganisms. NPs offer a new and effective “antibi-
otic” that could work against the resistance mechanism in Candida albicans.
The biogenic NPs offer a new generation of NPs that work as a carrier. These NPs offer the 
possibility to drive the toxicity effect to a specific target, in such way the collateral damage 
could be diminished.
However, the NPs toxicity mechanisms are not completely understood. The oxidative stress 
is one of the described mechanisms; it is possible to investigate other mechanisms involving 
similarity to oxidative stress. More studies are necessary to understand the influence that 
nanoparticles have in the Candida albicans resistance mechanisms and if this exposition could 
not generate new ones.
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